Simonbaker & Partners LLC continued to hold its position in Celgene Corporation (NASDAQ:CELG) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,061 shares of the biopharmaceutical company’s stock at the end of the 1st quarter. Simonbaker & Partners LLC’s holdings in Celgene Corporation were worth $381,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CELG. LGT Capital Partners LTD. raised its stake in shares of Celgene Corporation by 132.1% during the first quarter. LGT Capital Partners LTD. now owns 213,555 shares of the biopharmaceutical company’s stock valued at $26,573,000 after purchasing an additional 121,555 shares during the period. Rothschild Investment Corp IL raised its stake in shares of Celgene Corporation by 0.5% during the first quarter. Rothschild Investment Corp IL now owns 83,645 shares of the biopharmaceutical company’s stock valued at $10,408,000 after purchasing an additional 431 shares during the period. Penn Davis Mcfarland Inc. purchased a new stake in shares of Celgene Corporation during the first quarter valued at approximately $8,675,000. Motco raised its stake in shares of Celgene Corporation by 306.9% during the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 620 shares during the period. Finally, Douglas Lane & Associates LLC raised its stake in shares of Celgene Corporation by 3.0% during the first quarter. Douglas Lane & Associates LLC now owns 391,993 shares of the biopharmaceutical company’s stock valued at $48,776,000 after purchasing an additional 11,419 shares during the period. Institutional investors own 79.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/11/simonbaker-partners-llc-maintains-holdings-in-celgene-corporation-celg.html.

In other news, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the sale, the director now owns 9,250 shares of the company’s stock, valued at $1,286,027.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 263,011 shares of company stock worth $35,078,473. 0.95% of the stock is currently owned by insiders.

Shares of Celgene Corporation (NASDAQ CELG) traded up 0.01% during midday trading on Monday, reaching $140.52. 1,292,854 shares of the company’s stock traded hands. The firm has a market capitalization of $109.94 billion, a P/E ratio of 43.52 and a beta of 1.89. The stock’s 50 day moving average price is $134.21 and its 200 day moving average price is $126.79. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.64.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s revenue was up 18.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.44 earnings per share. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

CELG has been the topic of a number of analyst reports. Vetr lowered shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a research note on Tuesday, August 29th. Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a research note on Monday, August 28th. BTIG Research reiterated a “buy” rating and set a $138.00 price objective on shares of Celgene Corporation in a research note on Wednesday, May 24th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and lifted their price objective for the company from $96.93 to $160.00 in a research note on Monday, July 31st. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $160.00 price objective on shares of Celgene Corporation in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $147.31.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.